Перейти к основному содержанию
AkademIndex

Продукты

Для разработчиков

AkademBaseОткрытый API экосистемы
Статья

Cancer‐Associated Fibroblast‐Mediated Cellular Crosstalk Supports Hepatocellular Carcinoma Progression

Mengjia SongCollaborative Innovation Center for Cancer Medicine,State Key Laboratory of Oncology in South China,Sun Yat‐sen University Cancer Center,Guangzhou,P. R. ChinaJunyi HeCollaborative Innovation Center for Cancer Medicine,State Key Laboratory of Oncology in South China,Sun Yat‐sen University Cancer Center,Guangzhou,P. R. ChinaQiuzhong PanCollaborative Innovation Center for Cancer Medicine,State Key Laboratory of Oncology in South China,Sun Yat‐sen University Cancer Center,Guangzhou,P. R. ChinaJieying YangCollaborative Innovation Center for Cancer Medicine,State Key Laboratory of Oncology in South China,Sun Yat‐sen University Cancer Center,Guangzhou,P. R. ChinaJingjing ZhaoCollaborative Innovation Center for Cancer Medicine,State Key Laboratory of Oncology in South China,Sun Yat‐sen University Cancer Center,Guangzhou,P. R. ChinaYaojun ZhangCollaborative Innovation Center for Cancer Medicine,State Key Laboratory of Oncology in South China,Sun Yat‐sen University Cancer Center,Guangzhou,P. R. ChinaYue HuangCollaborative Innovation Center for Cancer Medicine,State Key Laboratory of Oncology in South China,Sun Yat‐sen University Cancer Center,Guangzhou,P. R. ChinaYan TangCollaborative Innovation Center for Cancer Medicine,State Key Laboratory of Oncology in South China,Sun Yat‐sen University Cancer Center,Guangzhou,P. R. ChinaQijing WangCollaborative Innovation Center for Cancer Medicine,State Key Laboratory of Oncology in South China,Sun Yat‐sen University Cancer Center,Guangzhou,P. R. ChinaJia HeCollaborative Innovation Center for Cancer Medicine,State Key Laboratory of Oncology in South China,Sun Yat‐sen University Cancer Center,Guangzhou,P. R. ChinaJiamei GuCollaborative Innovation Center for Cancer Medicine,State Key Laboratory of Oncology in South China,Sun Yat‐sen University Cancer Center,Guangzhou,P. R. ChinaYongqiang LiCollaborative Innovation Center for Cancer Medicine,State Key Laboratory of Oncology in South China,Sun Yat‐sen University Cancer Center,Guangzhou,P. R. ChinaShiping ChenCollaborative Innovation Center for Cancer Medicine,State Key Laboratory of Oncology in South China,Sun Yat‐sen University Cancer Center,Guangzhou,P. R. ChinaJianxiong ZengCollaborative Innovation Center for Cancer Medicine,State Key Laboratory of Oncology in South China,Sun Yat‐sen University Cancer Center,Guangzhou,P. R. ChinaZiqi ZhouCollaborative Innovation Center for Cancer Medicine,State Key Laboratory of Oncology in South China,Sun Yat‐sen University Cancer Center,Guangzhou,P. R. ChinaChaopin YangCollaborative Innovation Center for Cancer Medicine,State Key Laboratory of Oncology in South China,Sun Yat‐sen University Cancer Center,Guangzhou,P. R. ChinaYulong HanCollaborative Innovation Center for Cancer Medicine,State Key Laboratory of Oncology in South China,Sun Yat‐sen University Cancer Center,Guangzhou,P. R. ChinaHao ChenCollaborative Innovation Center for Cancer Medicine,State Key Laboratory of Oncology in South China,Sun Yat‐sen University Cancer Center,Guangzhou,P. R. ChinaTong XiangCollaborative Innovation Center for Cancer Medicine,State Key Laboratory of Oncology in South China,Sun Yat‐sen University Cancer Center,Guangzhou,P. R. ChinaDesheng WengCollaborative Innovation Center for Cancer Medicine,State Key Laboratory of Oncology in South China,Sun Yat‐sen University Cancer Center,Guangzhou,P. R. ChinaJian‐Chuan XiaCollaborative Innovation Center for Cancer Medicine,State Key Laboratory of Oncology in South China,Sun Yat‐sen University Cancer Center,Guangzhou,P. R. China
2021en
ABI

Аннотация

BACKGROUND AND AIMS: Cancer-associated fibroblasts (CAFs) are key players in multicellular, stromal-dependent alterations leading to HCC pathogenesis. However, the intricate crosstalk between CAFs and other components in the tumor microenvironment (TME) remains unclear. This study aimed to investigate the cellular crosstalk among CAFs, tumor cells, and tumor-associated neutrophils (TANs) during different stages of HCC pathogenesis. APPROACH AND RESULTS: In the HCC-TME, CAF-derived cardiotrophin-like cytokine factor 1 (CLCF1) increased chemokine (C-X-C motif) ligand 6 (CXCL6) and TGF-β secretion in tumor cells, which subsequently promoted tumor cell stemness in an autocrine manner and TAN infiltration and polarization in a paracrine manner. Moreover, CXCL6 and TGF-β secreted by HCC cells activated extracellular signal-regulated kinase (ERK) 1/2 signaling of CAFs to produce more CLCF1, thus forming a positive feedback loop to accelerate HCC progression. Inhibition of ERK1/2 or CLCF1/ciliary neurotrophic factor receptor signaling efficiently impaired CLCF1-mediated crosstalk among CAFs, tumor cells, and TANs both in vitro and in vivo. In clinical samples, up-regulation of the CLCF1-CXCL6/TGF-β axis exhibited a marked correlation with increased cancer stem cells, "N2"-polarized TANs, tumor stage, and poor prognosis. CONCLUSIONS: This study reveals a cytokine-mediated cellular crosstalk and clinical network involving the CLCF1-CXCL6/TGF-β axis, which regulates the positive feedback loop among CAFs, tumor stemness, and TANs, HCC progression, and patient prognosis. These results may support the CLCF1 cascade as a potential prognostic biomarker and suggest that selective blockade of CLCF1/ciliary neurotrophic factor receptor or ERK1/2 signaling could provide an effective therapeutic target for patients with HCC.

Перевод пока недоступен

Идентификаторы

Цитирования и источники

Цитирований: 2Использованных источников: 0